THERAPEUTIC ANTI-BODY SERVICES TECHNOLOGIES (Q2035366)

From EU Knowledge Graph
Revision as of 04:32, 20 March 2020 by DG Regio (talk | contribs) (‎Removed claim: co-financing rate (P837): 50.000001327108414 percent)
Jump to navigation Jump to search
Project in Italy financed by DG Regio
Language Label Description Also known as
English
THERAPEUTIC ANTI-BODY SERVICES TECHNOLOGIES
Project in Italy financed by DG Regio

    Statements

    country
    Italy
    0 references
    EU contribution
    188,379.49 Euro
    0 references
    budget
    376,758.97 Euro
    0 references
    start time
    12 December 2016
    0 references
    expected end time
    6 July 2019
    0 references
    beneficiary name (string)
    EXIRIS S.R.L.
    0 references
    beneficiary
    Q282251
    0 references
    coordinate location

    41°53'35.95"N, 12°28'58.55"E
    0 references
    summary
    GLI ANTICORPI SONO AGENTI TERAPEUTICI DI GRANDE SUCCESSO CHE VENGONO UTILIZZATI PER IL TRATTAMENTO DI MALATTIE ONCOLOGICHE, INFIAMMATORIE, AUTO IMMUNI E CARDIOVASCOLARI. IL NUMERO DI FARMACI BASATI SU ANTICORPI Ê IN CONTINUA CRESCITA (Italian)
    0 references

    Identifiers

    Italian Unique Project Code
    F81B18000200007
    0 references
     
    Retrieved from "https://linkedopendata.eu/w/index.php?title=Item:Q2035366&oldid=2483131"